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Polymyxins have been the only alternative therapeutic option for the treatment of serious infections caused by multidrug-resis-
tant Acinetobacter baumannii or Pseudomonas aeruginosa isolates. For this reason, it is of crucial importance that susceptibility
tests provide accurate results when testing these drug-pathogen combinations. In this study, the effect of cation concentration
variability found on different commercial brands of Mueller-Hinton agar (MHA) for testing polymyxin B susceptibility was eval-
uated. The polymyxin B susceptibilities determined using Etest and disk diffusion were compared to those determined by the
CLSI reference broth microdilutionmethod. In general, the polymyxin BMIC values were higher when determined by Etest than
when determined by broth microdilution against both A. baumannii and P. aeruginosa isolates. A high very major error rate
(10%) was observed, as well as a trend toward lower MICs, compared to those determined by broth microdilution when the
Merck MHAwas tested by Etest. Poor essential agreement rates (10 to 70%) were observed for P. aeruginosawhen all MHA
brands were tested by Etest. Although an excellent categorical agreement rate (100%) was seen between the disk diffusion and
broth microdilution methods for P. aeruginosa, larger zones of inhibition were shown obtained using the Merck MHA. The high
cation concentration variability found for the MHA brands tested correlated to the low accuracy, and discrepancies in the poly-
myxin BMICs were determined by Etest method, particularly for P. aeruginosa isolates.
Acinetobacter baumannii and Pseudomonas aeruginosa are im-portant nosocomial pathogens worldwide. These microor-
ganisms are noted for their intrinsic resistance to antibiotics and
for their ability to acquire genes encoding resistance determi-
nants. Unfortunately, the accumulation of distinctmechanisms of
resistance leads to the development ofmultidrug-resistant (MDR)
isolates. The emergence ofMDR isolates, including those resistant
to polymyxins is a major concern. Association of multiple resis-
tance mechanisms limits significantly the choices for treating
most of the hospital-acquired infections caused by nonfermenting
Gram-negative bacilli (19).
Polymyxins are polycationic peptides that act in the Gram-
negative bacterium cell wall, promoting disruption of the mem-
brane and loss of genetic material, leading to cellular death. In the
1960s, polymyxins were themajor therapeutic option available for
treating A. baumannii and P. aeruginosa infections. However,
their use was replaced bymore-active and less-toxic antimicrobial
agents such as cephalosporins and aminoglycosides (10, 18) in the
following two decades. In the 1990s, the clinical use of polymyxins
was reestablished due to the emergence ofMDRA. baumannii and
P. aeruginosa isolates, especially those resistant to carbapenems. In
the meantime, polymyxins have been considered the only reason-
able option for treatingmost serious infections caused byMDRA.
baumannii or P. aeruginosa isolates (3, 19, 27). As the need for
polymyxin usage increases in the clinical setting, routinemicrobi-
ology laboratories must perform the polymyxin susceptibility
testing under high-quality standard conditions. Since the cation
composition of Mueller-Hinton agar (MHA) may vary among
manufacturers and even among distinct lots of the samemanufac-
turer (13), the aim of the present study was to determine the in-
fluence of different commercial brands of MHA for testing the
polymyxin B susceptibility ofA. baumannii andP. aeruginosa clin-
ical isolates.
(This study was presented in part at the 50th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Boston,
MA, USA, in 2010 [poster presentation D1539].)
MATERIALS AND METHODS
Polymyxin B susceptibility testing. A total of 10 clinical isolates of A.
baumannii and 10 P. aeruginosa, recovered from bloodstream and respi-
ratory tract infections, were selected for the present study. Isolates were
collected fromFebruary toAugust 2007 as part ofmulticenter studywhich
enrolled eight different hospitals located in the São Paulo metropolitan
area. To represent distinct hospitals, at least one isolate per hospital was
selected.Nonduplicate isolates per patient were included in the study. The
susceptibility to polymyxin B was determined by Etest method according
to the manufacturer’s instructions (AB bioMérieux, Marcy l’Étoile,
France) and by the disk diffusion (Oxoid, Basingstoke, United Kingdom)
method, except forA. baumannii, according to themethods of theClinical
and Laboratory Standards Institute (CLSI) (6). The Etest and disk diffu-
sion techniques were performed using four distinct commercial brands of
MHA. The medium powder was obtained from Oxoid (Basingstoke,
United Kingdom), lot 579019; Difco (BD Diagnostic Systems, Sparks,
MD), lot 7093809; Merck (Darmstadt, Germany), lot VL698237; and Hi-
media (Mumbai, India), lot 26206. Broth microdilution was selected as
the reference method using the four commercial brands of Mueller-Hin-
ton broth (MHB): Oxoid, lot 724245; Difco, lot 9106707; Merck, lot
VL136293; and Himedia, lot 89292. The MHB was prepared from the
powder and supplementedwithCa2 andMg2 according toCLSI guide-
lines (6). The polymyxin B sulfatewas acquired fromSigma-Aldrich (Ger-
many). The percent essential agreement  1-log2 variation in the poly-
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myxin B MICs determined by broth microdilution using distinct MHB
brands was observed (data not shown). In this manner, the reference
polymyxin B MIC was set as the calculated mean using the MIC values
obtained by testing the four brands of MHB in triplicate.
The Etest and disk diffusion tests were performed in triplicate and read
by three observers blinded to the commercial brand of MHA. The final
Etest MICs and diameter inhibition zones for polymyxin B were calcu-
lated as themean of all individual results that included the three observers
on three distinct occasions. The results were interpreted according to
CLSI parameters, which are as follows for zone diameters: 12 mm 
susceptible (S) and11mm resistant (R) forP. aeruginosa andMICs of
2 g/ml (S), 4 g/ml (intermediate [I]), and  8 g/ml (R) for P.
aeruginosa andMICs of2g/ml (S) and 4g/ml (R) forAcinetobacter
spp. (7). Escherichia coliATCC25922 and P. aeruginosaATCC27853were
tested as the quality control strains.
Essential agreement was defined as when the Etest results agreed
within 1-log2 dilution compared to the reference broth microdilution
test. A result was determined to be discrepant if therewas2-log2 dilution
difference between test results. Categorical agreement was defined if the
test results were within the same susceptibility category, and errors were
ranked as follows: verymajor error, false-susceptible result by Etest;major
error, false-resistant result by Etest; and minor error, intermediate result
by Etest method and resistant or susceptible category by broth microdi-
lution test (25).
Determination of ions concentration in the MHA and MHB of dis-
tinct commercial brands. An aliquot of 100 mg of each culture medium
brand was diluted in 3 ml of HNO3 and 2 ml of H2O2 and then subjected
to digestion in a microwave oven for 30 min. The Mueller-Hinton me-
dium solutionswere transferred to a volumetric flask, anddeionizedwater
was added to a final volume of 25 ml. The concentrations of calcium,
magnesium, manganese, iron, and zinc contained in distinct commercial
brands of Mueller-Hinton agar and broth were quantified by inductively
coupled plasma optical emission spectrometry (ICP-OES) in a Perkin-
Elmer 3000 DV at the Laboratório de Química, Universidade Estadual de
Campinas, UNICAMP, São Paulo, Brazil (20).
RESULTS
Polymyxin B susceptibility tests. Considering the results
achieved by the referencemethod (brothmicrodilution) using the
fourMHB tested, 2 of 10A. baumannii isolateswere determined to
be resistant to polymyxin B (MIC  4 g/ml). All P. aeruginosa
isolates (MICs ranging from 0.25 to 1 g/ml) were susceptible
to polymyxin B (Table 1). In general, polymyxin B MIC values
were higher as determined by Etest than as determined by broth
microdilution against both A. baumannii (2 log2) and P. aerugi-
nosa (3 log2) isolates. An essential agreement of 100%was found
for Difco media when used to test A. baumannii isolates. In con-
trast, the essential agreement rates between the broth microdilu-
tion and the Etest were 80% for the Merck and Oxoid MHAs and
90% for Himedia. A slight trend toward lowerMICs was observed
using Merck MHA, leading to the miscategorization of a poly-
myxin-resistant isolate as susceptible (very major error).
Poor essential agreement was observed between the Etest and
brothmicrodilution polymyxin BMICs using allMHAbrands for
testing against P. aeruginosa. Although no very major and major
errors were observed, the minor errors rates were determined to
be 20 and 40% when testing Oxoid and Himedia media, respec-
tively. The disk diffusion method presented 100% categorical
TABLE 1 Polymyxin B susceptibility results for Acinetobacter baumannii and Pseudomonas aeruginosa as determined by Etest and disk diffusion
testing of four distinct commercial MHA products and comparison of the results to those of the reference method, broth microdilutiona
Strain
Broth microdilution
MIC (g/ml)
Etest MIC (g/ml) Disk diffusion zone diam (mm)
Oxoid Difco Merck Himedia Oxoid Difco Merck Himedia
A. baumannii
A009 4 (R) 16 (R) 6 (R) 1.5 (S) 3 (R) – – – –
A026 4 (R) 4 (R) 4 (R) 3 (R) 4 (R) – – – –
A028 0.25 (S) 0.5 (S) 0.5 (S) 1.5 (S) 0.38 (S) – – – –
A041 0.5 (S) 0.5 (S) 0.5 (S) 0.19 (S) 0.5 (S) – – – –
A049 0.25 (S) 0.5 (S) 0.5 (S) 0.19 (S) 0.5 (S) – – – –
A210 0.5 (S) 0.5 (S) 0.75 (S) 0.125 (S) 0.5 (S) – – – –
A220 0.5 (S) 0.5 (S) 0.5 (S) 0.19 (S) 0.125 (S) – – – –
A228 0.5 (S) 1.5 (S) 0.5 (S) 0.25 (S) 0.5 (S) – – – –
A256 0.5 (S) 0.5 (S) 0.5 (S) 0.25 (S) 0.38 (S) – – – –
A263 0.5 (S) 1 (S) 0.5 (S) 0.19 (S) 0.5 (S) – – – –
% EAb (1 log2) 80 100 80 90 – – – –
P. aeruginosa
P008 0.5 (S) 2 (S) 0.75 (S) 0.125 (S) 2 (S) 16 (S) 17 (S) 18 (S) 17 (S)
P097 0.5 (S) 3 (I) 1.5 (S) 0.38 (S) 2 (S) 16 (S) 16 (S) 18 (S) 17 (S)
P098 1 (S) 4 (I) 1.5 (S) 0.38 (S) 3 (I) 15 (S) 16 (S) 17 (S) 15 (S)
P101 0.5 (S) 0.5 (S) 1 (S) 0.064 (S) 0.75 (S) 16 (S) 21 (S) 27 (S) 20 (S)
P196 0.5 (S) 1.5 (S) 1.5 (S) 0.25 (S) 1.5 (S) 16 (S) 17 (S) 18 (S) 16 (S)
P231 0.25 (S) 1.5 (S) 2 (S) 0.25 (S) 3 (I) 15 (S) 16 (S) 18 (S) 16 (S)
P316 0.5 (S) 1.5 (S) 1.5 (S) 0.38 (S) 1.5 (S) 16 (S) 16 (S) 19 (S) 16 (S)
P327 0.5 (S) 2 (S) 1.5 (S) 0.5 (S) 3 (I) 14 (S) 15 (S) 16 (S) 15 (S)
P337 0.25 (S) 1.5 (S) 1.5 (S) 0.5 (S) 1.5 (S) 16 (S) 16 (S) 17 (S) 16 (S)
P342 1 (S) 1.5 (S) 1.5 (S) 0.19 (S) 4 (I) 14 (S) 16 (S) 17 (S) 16 (S)
% EA (1 log2) 20 40 70 10 – – – –
a Means of triplicate reader results are presented. Interpretations are indicated in parentheses: I, intermediate; R, resistant; and S, susceptible (according to CLSI standards, 2011). –,
Not applicable.
b % EA, percent essential agreement.
Inﬂuence of MHA on Polymyxin B Susceptibility
July 2012 Volume 50 Number 7 jcm.asm.org 2415
agreement with those for broth microdilution for all of the P.
aeruginosa isolates tested. However, MerckMHA produced larger
zones of inhibition than those of other MHA brands. Upon com-
paring the results of polymyxin BMIC as determined by Etest, we
found no disagreement among the three readers for all of the
MHA brands except for the Merck MHA (20% within 2-log2
dilutions).
Dosage of ion concentration in the MHA andMHB. The ion
concentrations for the MHB andMHA commercial brands tested
are presented in Table 2. The concentrations of the evaluated cat-
ions, such as calcium,magnesium, iron, and zinc, differed for each
brand of MHB. Manganese concentrations were below of the de-
tection limit for allMHB brands. Although the highest concentra-
tions of calcium and magnesium were detected in the Oxoid
MHB, they were far below those recommended by the CLSI. The
zinc content in theOxoidMHBwas 2- and 3-fold higher than that
seen in the Himedia and Difco MHBs, respectively. Iron was de-
tected but was not quantified in the Merck and Himedia MHBs.
However, the iron concentration was quite similar when we com-
pared the Oxoid and Difco MHBs (Table 2).
A higher variation in ion concentrations was observed among
the distinct MHA brands, as shown in the Table 2. The calcium
andmagnesium concentrations in the OxoidMHAwere 20.9 and
13.3 mg/liter, respectively. The Merck MHA had the lowest cal-
cium concentration (7.5 mg/liter), while Difco and Merck MHA
showed the lowest magnesium concentrations (4.9 and 6.2 mg/
liter, respectively). Oxoid and Himedia MHAs showed more ele-
vated calcium concentrations than the other two commercial
brands. Only theMerckMHApresented a detectable zinc concen-
tration in its composition. The Difco and Himedia MHA brands
presented insufficient iron concentration to be detected and
quantified, respectively, by ICP-OES.
DISCUSSION
The increasing incidence of hospital-acquired infections caused
by MDR P. aeruginosa and A. baumannii worldwide has placed
polymyxin agents as one of the last therapeutic options for treat-
ment of these infections (15). However, accurate susceptibility
testing for these compounds, which is known to be essential for
therapeutic management, is still problematic in routine clinical
microbiology laboratories. It has been reported that polymyxin
MICsmay not be reproducible and that many factors influence its
determination, such as the inoculumand the cation concentration
content of the Mueller-Hinton medium (2, 14, 22, 24). In addi-
tion, it has been observed thatMICs obtained by agar dilution and
Etest methods are higher than those obtained by the reference
broth microdilution technique (17). Moreover, the disk diffusion
technique has been considered an unreliable technique for pre-
dicting the susceptibility to polymyxins among A. baumannii iso-
lates. Regardless of the antimicrobial susceptibility technique used
for determining the antimicrobial category of susceptibility, the
cation concentrations of the Mueller-Hinton medium should be
adjusted for reliable test results since high or low cation concen-
trations may result in false resistance (major error) or false sus-
ceptibility (very major error), respectively (6).
CLSI guidelines recommend a calcium concentration ranging
from 20 to 25 mg/liter and a magnesium concentration ranging
from 10 to 12.5 mg/liter to assure reliable antimicrobial suscepti-
bility results (6). The calcium and magnesium concentrations
measured for each of theMHBbrands evaluated in our studywere
far below the recommendations, confirming that the cation con-
centration must be adjusted before testing, as recommended by
CLSI guidelines. Each batch ofMHBused in the present study was
cation adjusted before use according to the initial concentration
measured. For this reason, no essential agreement discrepancies
were achieved by broth microdilution among the MHB brands
tested. The four distinct commercial brands of MHA presented
higher concentrations of calcium and magnesium compared to
those of MHB from the same manufacturer. However, none of
them displayed the correct concentrations of calcium andmagne-
siumas recommended by theCLSI. The higher polymyxin BMICs
exhibited by Etest and the smaller-diameter zones of inhibition
determined by disk diffusion were probably due to distinct cation
concentrations in the MHA brands tested. The polymyxin resis-
tance is controlled by two-component regulatory systems, includ-
ing PmrA/B, PhoP/Q, and also the more recently described
ParR/S. These systems respond to environmental variations such
as an elevated calciumor a lowmagnesium concentration, distinct
pHs, and the presence of iron in the medium. The environmental
signals are detected by the sensor kinase gene that modifies the
expression of the second gene, a response regulator, which in turn
promotes modifications in the Gram-negative lipopolysaccha-
TABLE 2 Ion concentrations in several distinct commercial brands of Mueller-Hinton broth and agar
Culture medium Commercial brand
Ion concn (mg/liter)a
Calcium Magnesium Manganese Iron Zinc
MHB Oxoid 3.1 3.9 0.04* 0.6 0.6
Difco 2.4 2.5 0.04* 0.8 0.2
Merck 2.1 0.6 0.04* 0.5† 0.2†
Himedia 2.2 1.1 0.04* 0.5† 0.3
MHA Oxoid 20.9 13.3 0.09* 2.2† 0.7†
Difco 16.1 4.9 0.09* 0.6* 0.7†
Merck 7.5 6.2 19.3 2.2† 1.1
Himedia 25.3 31.2 0.09* 2.2† 0.7†
CLSI parametersb 20–25 10–12.5 – – –
a *, The concentration was lower than the minimal value for detection; †, the concentration was lower than the minimal value for quantification; –, no specific CLSI
recommendation.
b That is, the cation concentrations recommended for testing according to CLSI standards, 2009.
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ride, leading to polymyxin resistance (1, 4, 12, 21, 24). Previous
studies have also reported increased polymyxin B and colistin
MICs against P. aeruginosa andA. baumannii associated with high
calcium ormagnesium concentration in culturemedia (9, 11, 26).
It is also reported that high concentrations of magnesium can
interfere with the activity of other antimicrobials, such as fluoro-
quinolones and carbapenems (5, 8).
Our results corroborate the need for cation supplementation
in the culturemedium as recommended by the CLSI (6). To know
the right amount to be supplemented, we must know the exact
cation content of the Mueller-Hinton medium, especially for the
MHA. Due to MHA’s solid nature, cation quantification cannot
be usually carried out at the biochemistry section of the clinical
laboratory as we could perform for MHB. In our opinion, the
cation concentrations of eachMueller-Hinton lot should be stated
on the labels of theMueller-Hinton bottles since this information
is not available even on themediumQuality Assurance Certificate
of most of the manufacturers. In our study, the cation concentra-
tionwas described in just oneMueller-Hinton bottle fromone out
four brands tested. The Mueller-Hinton bottles from other man-
ufacturers simply stated that the calcium andmagnesium concen-
trations were in accordance with CLSI guidelines. Manufacturers
were asked about the calcium and magnesium content of the re-
spective lots tested in our study. The cation concentration pro-
vided by one of the manufacturers was in accordance with our
measurement. For the remaining media, the information was ei-
ther not given after contact (two brands) or the informed concen-
trations were not in accordance with our measurement (one
brand).
Our results demonstrate that the polymyxin B susceptibility
phenotype varied according to the MHA brand tested, probably
due to the two-component regulatory system response. Clinical
microbiology laboratories should be aware of this in order to
avoid reporting erroneous susceptibility results for polymyxin B.
While cation supplementation is not readily available since most
of themanufacturers do not state the exact cation content on their
MHA bottles, laboratory technicians should attempt to gentami-
cin and tetracycline results tested against E. coli ATCC 25922 and
P. aeruginosa ATCC 27853 strains to detect unsatisfactory cation
content as recommended by the CLSI (6). If the results are inad-
equate for quality control strains, the use of a new medium lot is
recommended. Moreover, if the problem persists, even when us-
ing a new lot, the manufacturer should be contacted. Although
there is no CLSI recommendation for manganese, iron, or zinc
supplementation in the culture medium, diverse studies have
shown that these ions can also influence the antimicrobial suscep-
tibility tests results for other antimicrobial agents than polymyxin
(13, 16).
Polymyxin susceptibility rates remain quite elevated against
nonfermenting Gram-negative bacilli. Differences in the cation
composition of the MHA can generate categorical errors in the
polymyxin B susceptibility tests. Although the occurrence of such
errors is currently low, it is expected to increase as polymyxin
becomes more frequently prescribed for the treatment of infec-
tions caused byMDR pathogens and as MICs increase toward the
resistance breakpoint. Clinical microbiology laboratories must be
aware of polymyxin susceptibility methods discrepancies to avoid
reporting erroneous results. Moreover, resistant isolates detected
by Etest must be sent to a reference laboratory to confirm this
phenotype by reference brothmicrodilution. Also, we suggest that
manufacturers should state the exact cation content of eachMHA
lot on the bottle label since the measurement is not easily accom-
plished by the routine clinical microbiology laboratory. Mean-
while, laboratory technicians should pay attention to the gentami-
cin and tetracycline results for ATCC strains.
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